Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Anacetrapib , an inhibitor of cholesteryl ester transfer protein activity, increases plasma concentrations of high-density lipoprotein cholesterol , apolipoprotein A-I -I, apoA-II, and CETP.